Your Patients Need Aminosyn 3.5% M, Sulfite Free — Here's How to Help Them Get It

As a healthcare provider, few things are more frustrating than writing a prescription you know your patient needs and then learning the medication isn't available. The ongoing shortage of Aminosyn 3.5% M, Sulfite Free — and amino acid injection products broadly — has created real challenges for patients on parenteral nutrition and the clinical teams who care for them.

This guide provides actionable steps you can take to help your patients navigate supply disruptions, find available product, and maintain uninterrupted nutritional support.

Current Availability of Aminosyn 3.5% M, Sulfite Free

As of 2026, Aminosyn 3.5% M, Sulfite Free remains in intermittent supply. The product is manufactured by Pfizer (Hospira) / ICU Medical, and availability varies by distributor and region. ASHP continues to list amino acid products in active shortage, and ASPEN's 2025 shortage management recommendations remain in effect.

The broader amino acid product market includes multiple alternatives — Travasol 10%, Clinisol 15% Sulfite-Free, FreAmine III 10%, Aminosyn II (various concentrations), and Clinimix/Clinimix E premixed solutions — but supply of these products is also variable. No single product can be guaranteed to be consistently available.

For the latest shortage details, see our clinical shortage briefing for providers.

Why Your Patients Can't Find It

Understanding the reasons behind the shortage helps you communicate effectively with patients and set realistic expectations:

• Limited manufacturer base: Only 2 to 3 companies produce amino acid injections for the U.S. market. Any single disruption has outsized impact.
• Recall aftermath: ICU Medical's 2023 recall of Aminosyn II 15% removed product from the supply chain and affected manufacturing capacity across the Aminosyn family.
• IV supply chain stress: Post-2024 hurricane damage to IV manufacturing infrastructure created cascading effects on all sterile injectable products.
• Distributor allocation: When supply is limited, distributors impose allocation limits, meaning even pharmacies with demand may not receive their full orders.
• Home vs. hospital competition: Hospital systems with purchasing contracts may have preferential access, leaving home infusion patients more vulnerable to shortages.

What Providers Can Do: 5 Practical Steps

Step 1: Write Prescriptions with Flexibility

When prescribing amino acid products for parenteral nutrition, consider writing orders that allow for product substitution. Rather than specifying Aminosyn 3.5% M exclusively, include language such as "Aminosyn 3.5% M, Sulfite Free, or therapeutic equivalent amino acid injection." This gives the dispensing pharmacy flexibility to fill with available product without requiring a new prescription or callback to your office.

If your institution uses electronic prescribing, work with your pharmacy team to create order sets that include substitution protocols for amino acid products.

Step 2: Pre-Authorize Alternative Products

Don't wait for a supply crisis to determine which alternatives are appropriate for your patients. For each parenteral nutrition patient:

• Document acceptable substitute amino acid products in the chart
• Include notes on route of administration requirements (peripheral vs. central access)
• Specify electrolyte supplementation instructions for products without preset electrolytes
• Update the home infusion pharmacy on authorized alternatives

This proactive approach saves days of delay when the primary product becomes unavailable.

Step 3: Direct Patients to Medfinder

Medfinder for Providers is a free tool that helps locate pharmacies with specific medications in stock. You can use it directly during a patient visit or provide the link to patients and caregivers for self-service searching.

For parenteral nutrition patients, the most relevant pharmacies will be home infusion providers. Medfinder can help identify providers in the patient's geographic area that currently have amino acid products available.

Step 4: Engage the Nutrition Support Team

If your institution has a nutrition support team or consult service, involve them early when supply disruptions occur. These teams can:

• Evaluate whether dose optimization is possible (reducing protein targets temporarily during shortage periods per ASPEN guidelines)
• Assess opportunities for enteral nutrition advancement to reduce PN dependence
• Coordinate with pharmacy on compounding alternatives
• Provide patient education on product changes

For providers without institutional nutrition support resources, ASPEN's 2025 Parenteral Nutrition Product Shortage Recommendations provide detailed clinical guidance.

Step 5: Coordinate with Home Infusion Pharmacies

Home infusion pharmacies are the primary dispensers of parenteral nutrition for outpatients. Maintaining open communication with your patients' infusion pharmacy is critical during shortages. Specifically:

• Confirm which amino acid products the pharmacy currently has access to
• Provide advance notice of new PN starts so the pharmacy can source product
• Respond promptly to pharmacy calls about product substitutions
• Consider establishing relationships with multiple home infusion providers to give patients options if one provider's supply is disrupted

Alternative Amino Acid Products to Consider

The following products are considered therapeutically equivalent to Aminosyn 3.5% M on a gram-for-gram basis, per ASPEN guidelines:

• Travasol 10% (Baxter): No preset electrolytes; central line required. Generally more available.
• Clinisol 15% Sulfite-Free (Baxter): High concentration; central line required. Sulfite free.
• FreAmine III 10%: No preset electrolytes; central line required.
• Aminosyn II Sulfite-Free (7%, 8.5%, 10%, 15%): Related product; different amino acid profile; no preset electrolytes.
• Clinimix/Clinimix E (Baxter): Premixed amino acid/dextrose; Clinimix E includes electrolytes. May simplify compounding.

Important clinical note: Aminosyn 3.5% M is one of the few products suitable for peripheral administration. If switching to a higher-concentration product, ensure the patient has appropriate central venous access or evaluate the need for line placement.

For a complete comparison, see: Alternatives to Aminosyn 3.5% M, Sulfite Free.

Workflow Tips for Managing the Shortage

• Build shortage protocols into your EHR. Create standardized order sets for amino acid product substitution, including electrolyte adjustment templates.
• Track patient supply status. For patients on home PN, add a supply status check to follow-up visit templates. Ask about remaining supply and pharmacy communication at each encounter.
• Educate patients proactively. Share patient-facing resources about the shortage so patients understand why their product might change and what alternatives are safe. Recommended reading for patients: Aminosyn 3.5% M, Sulfite Free Shortage Update for Patients.
• Document everything. When making product substitutions due to shortage, document the clinical rationale in the patient chart. This supports insurance coverage, quality metrics, and continuity of care.
• Report shortages. Report ongoing supply issues to the FDA Drug Shortage Staff and your institution's pharmacy and therapeutics committee. Data from the field helps drive policy responses.

Final Thoughts

The amino acid product shortage requires providers to be proactive, flexible, and communicative. By pre-authorizing alternatives, directing patients to tools like Medfinder for Providers, and maintaining close coordination with home infusion pharmacies, you can help ensure your patients continue to receive the nutritional support they need — even when specific products are hard to find.

For additional provider resources, see our clinical shortage briefing and guide to helping patients save money on Aminosyn 3.5% M, Sulfite Free.